You are leaving this site!
By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?
When you browse the BIVIGAM Website your personal information is not revealed to us. Details such as your name and e-mail address remain anonymous. As usual with virtually all web pages, the only initial information recorded is your IP address, which helps us to administer our Website and identify broad demographic information, such as your browser type and geographic location.
ADMA Biologics collects personally identifiable information, such as names, addresses, e-mail addresses and the like, only when voluntarily provided by a Website user. ADMA Biologics does not want to receive confidential, proprietary or personal medical information through Website communications.
Any communication with the BIVIGAM Website or any other e-mail transmission to ADMA Biologics on this Website is non-confidential. ADMA Biologics has no obligation to refrain from reproducing, publishing or otherwise using third-party information for any purpose, and ADMA Biologics may use the content of any such communication, including any ideas or know how disclosed therein for ADMA Biologics’ own commercial purposes. Whoever transmits any communication to this Website or otherwise to ADMA Biologics is solely responsible for its accuracy and completeness. This site is intended to provide a service to users.
All rights not expressly granted herein are reserved to ADMA Biologics.
BIVIGAM is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for the treatment of patients with primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).
WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE